Nomani Homa, Mohammadpour Amir Hooshang, Reiner Željko, Jamialahmadi Tannaz, Sahebkar Amirhossein
School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9179156314, Iran.
Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9179156314, Iran.
J Cardiovasc Dev Dis. 2021 Feb 26;8(3):24. doi: 10.3390/jcdd8030024.
Atrial fibrillation (AF) occurring after cardiac surgery, post-operative AF (POAF), is a serious and common complication of this treatment. POAF may be life-threatening and the available preventive strategies are insufficient or are associated with significantly increased risk of adverse effects, especially in long-term use. Therefore, more appropriate treatment strategies are needed.
In this paper, the efficacy, safety, and other aspects of using statins in the prevention of POAF focusing on their anti-inflammatory effects are reviewed.
Recent studies have suggested that inflammation has a significant role in POAF, from the first AF episode to its serious complications including stroke and peripheral embolism. On the other hand, statins, the most widely used medications in cardiovascular patients, have pleiotropic effects, including anti-inflammatory properties. Therefore, they may potentially be effective in POAF prevention. Statins, especially atorvastatin, appear to be an effective option for primary prevention of POAF, especially in patients who had coronary artery bypass grafting (CABG), a cardiac surgery treatment associated with inflammation in the heart muscle. However, several large studies, particularly with rosuvastatin, did not confirm the beneficial effect of statins on POAF. One large clinical trial reported higher risk of acute kidney injury (AKI) following high-dose rosuvastatin in Chinese population. In this study, rosuvastatin reduced the level of C-reactive protein (CRP) but did not reduce the rate of POAF.
Further studies are required to find the most effective statin regimen for POAF prevention with the least safety concern and the highest health benefits.
心脏手术后发生的心房颤动(AF),即术后房颤(POAF),是这种治疗中一种严重且常见的并发症。POAF可能危及生命,现有的预防策略不足或与不良反应风险显著增加相关,尤其是长期使用时。因此,需要更合适的治疗策略。
本文综述了他汀类药物在预防POAF方面的疗效、安全性及其他方面,重点关注其抗炎作用。
近期研究表明,炎症在POAF中起重要作用,从首次房颤发作到其严重并发症,包括中风和外周栓塞。另一方面,他汀类药物是心血管疾病患者中使用最广泛的药物,具有多种作用,包括抗炎特性。因此,它们可能对预防POAF有效。他汀类药物,尤其是阿托伐他汀,似乎是POAF一级预防的有效选择,特别是在接受冠状动脉旁路移植术(CABG)的患者中,CABG是一种与心肌炎症相关的心脏手术治疗。然而,几项大型研究,特别是关于瑞舒伐他汀的研究,并未证实他汀类药物对POAF的有益作用。一项大型临床试验报告称,中国人群中高剂量瑞舒伐他汀治疗后急性肾损伤(AKI)风险更高。在这项研究中,瑞舒伐他汀降低了C反应蛋白(CRP)水平,但未降低POAF发生率。
需要进一步研究以找到预防POAF最有效的他汀类药物治疗方案,同时安全性担忧最小且健康效益最高。